Analyzing Chugai Pharmaceutical (OTCMKTS:CHGCY) and Milestone Pharmaceuticals (NASDAQ:MIST)

Chugai Pharmaceutical (OTCMKTS:CHGCY) and Milestone Pharmaceuticals (NASDAQ:MIST) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Chugai Pharmaceutical and Milestone Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chugai Pharmaceutical	$8.41 billion	8.68	$2.91 billion	$0.92	24.12
Milestone Pharmaceuticals	$1.55 million	84.74	-$63.06 million	($0.69)	-1.53

Chugai Pharmaceutical has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Chugai Pharmaceutical and Milestone Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chugai Pharmaceutical	0	2	1	1	2.75
Milestone Pharmaceuticals	1	1	4	1	2.71

Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 506.64%. Given Milestone Pharmaceuticals’ higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Chugai Pharmaceutical.

Volatility & Risk

Chugai Pharmaceutical has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Chugai Pharmaceutical and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chugai Pharmaceutical	35.09%	23.76%	19.92%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Summary

Chugai Pharmaceutical beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.